Enveda Therapeutics, Inc. announced that it has received $119 million in funding from a group of investors

On April 20, 2023, Enveda Therapeutics, Inc. closed the transaction. The company amended the terms of the transaction. The company received $119,000,000 total gross proceeds in an oversubscribed round of funding.

The transaction was led new investor Kinnevik AB, and included participation from new investor Henry R. Kravis, FPV Ventures, LLC, Dimension Capital Management LLC, returning investors True Venture Management, LLC, and WireFrame Partners. The company received $68,000,000 from series B, and $51,000,000 from series B-1. The company has raised $175,000,000 in funding till date. The company has received $51,000,000 in its final tranche closing.

As a part of transaction, Pegah Ebrahimi of FPV Ventures, LLC will join the company's board of directors.